Introduction
Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily and participates in a number of diverse biological actions, due to its distribution in almost all organs and tissues. This expression pattern includes the brain, where VDR expression has been detected in the hypothalamus, hippocampus, cortex and sub-cortical regions,1,2 which are essential for cognition. The active form of vitamin D, 1,25(OH)2D3, plays an important role in neuronal differentiation and maturation by controlling the synthesis of neurotrophic agents,1,3 and also by regulating the expression of numerous genes involved in neurotransmitter synthesis, predominantly in the hippocampus (Fig. 1).4,5
The VDR is well known for modulating the transcription of genes encoding proteins that execute the “classic” genomic functions of vitamin D for skeletal and mineral homeostasis. However, it also regulates the expression of several genes that mediate “non-classical” actions in non-calcemic tissues. Many of these “non-classical” actions are associated with decreased risk for disorders associated with ageing, including those linked to the nervous system.6,7 The elderly are particularly at risk for a number of degenerative disorders related to low serum calcidiol (25(OH)D3) levels. This is due to a decrease in ultraviolet radiation (UVR) exposure as a consequence of changes in lifestyle, particularly a decline in outdoor activity.8
Diet can also become less varied with age, resulting in low intake of vitamin D content.9 Most significant, however, is a decrease in the ability to synthesise cutaneous vitamin D after UVR exposure–a result of atrophic changes in the skin and a reduced level of the vitamin D precursor, 7-dehydrocholesterol.10 Investigation of the impact of vitamin D deficiency on the ageing brain is critical, with evidence linking low vitamin D status with poorer outcomes on one or more cognitive function tests,11,12 or a higher frequency of dementia,13 mood disorders,14 cognitive decline and Alzheimer’s disease (AD).15–17
The VDR gene is located on chromosome 12 (12q13.11) and contains several known polymorphisms. VDR-ApaI (G>T substitution) and VDR-BsmI (A>G substitution) are restriction fragment length polymorphisms (RFLPs) located at the intron between exon 8–9, and are considered to be silent single nucleotide polymorphisms (SNPs) as they do not change the amino acid sequence of the encoded VDR protein.15,16 They may, however, alter gene expression through regulation of messenger RNA.16,17 VDR-TaqI (T>C substitution) is a RFLP in exon 9, while the VDR-FokI polymorphism (T>C substitution) is situated at the start of the codon in exon 2 of the VDR gene.18 The VDR-Tru91 (G>A substitution) located within the intron 8 region has been studied to a lesser extent.16,19 Other polymorphisms in the 1A promoter region, including VDR-Cdx2, VDR-A1012G and VDR-G1520C, have also recently been reported.20
The objective of this study was to examine the relationship between eight vitamin D-related genetic polymorphisms and cognitive decline in an elderly cohort. Furthermore, dietary intake of vitamin D and other related markers were analysed to determine their influence on cognition.
Methods
Study design
A total of 650 participants (287 males and 363 females, aged 65–95 years) living independently in either a retirement village or within the community on the Central Coast, New South Wales were assessed for the prevalence of eight VDR genetic polymorphisms, dietary intake of vitamin D, and cognitive ability using the mini-mental state examination (MMSE). Following screening, all dementia participants were excluded from the study.
Informed consent was obtained from all participants prior to study participation. This cross-sectional study was approved by the University of Newcastle Human Research Ethics Committee (H-2008-0431), and the Occupational Health and Safety Committee (28.2009). The study was fully compliant with the Helsinki Declaration. The data used in the present study formed part of a larger Retirement Health and Lifestyle Study (RHLS) funded by an Australian Research Council Linkage Project Grant.
DNA analysis
VDR gene variants were examined using polymerase chain reaction (PCR) to amplify blood DNA, followed by RFLP analysis and gel electrophoresis. Initially, a QIAamp DNA blood mini-kit was used to extract DNA from whole blood using the QIAamp blood and body fluid spin protocol.21 The optimal PCR reaction mixture and temperature varied for each polymorphism examined. Table 1 provides the thermal cycling conditions for each VDR polymorphism, whilst Table 219,22–26 gives the primer sequence details for VDR-ApaI, VDR-BsmI, VDR-TaqI, VDR-FokI, VDR-Tru91, VDR-Cdx2, VDR-A1012G and VDR-NIaIII. RFLP was performed following PCR amplification, as described in Table 3. VDR-Cdx2 requires a nested primer allele-specific strategy for genotype scoring, eliminating the need for enzyme digestion. Examples of each genotype for each VDR polymorphism can be seen in Figure 2.
Table 1Summary of the PCR reagents and thermal cycling conditions for each VDR polymorphism
Gene variant | GoTaq® Green Master Mix, µL | Primer in 5 pmol, µL | DNA, µL | H2O, µL | Thermal cycling conditions |
---|
VDR-A1012G | 10 | 4 | 2 | 4 | 95°C x 2 min; 35 x [95°C x 30 sec; 58°C x 30 sec; 72°C x 30 sec]; 72°C x 7 min; hold at 15°C |
VDR-TaqI, VDR-ApaI, VDR-BsmI, VDR-FokI, VDR-Tru91*** | 10 | 4 | 2 | 4 | 95°C x 3 min; 35 x [95°C x 30 sec; 61°C x 30 sec; 72°C x 30 sec]; 72°C x 7 min; hold at 15°C |
VDR-Cdx2 G* VDR-Cdx2 A* | 10 10 | 2.4 1.6 | 2 2 | 4 4 | 95°C x 3 min; 35 x [95°C x 30 sec; 56°C x 45 sec; 72°C x 30 sec]; 72°C x 7 min; hold at 15°C |
VDR-NIaIII | 10 | 4 | 2 | 4 | 95°C x 2 min; 35 x [95°C x 30 sec; 58°C x 30 sec; 72°C x 30 sec]; 72°C x 7 min; hold at 15°C |
Table 2Primer sequences for each VDR polymorphism
Gene variant | Forward primer, 5′→3′ | Reverse primer, 5′→3′ | Fragment length, bp | Ref |
---|
VDR-A1012G | CCT CCT CTG TAA GAG GCG AAT AGC GAT | GGA CAG GTG AAA AAG ATG GGG TTC | 177 | [22] |
VDR-TaqI, VDR-ApaI*** | ACG TCT GCA GTG TGT TGG AC | TCA CCG GTC AGC AGT CAT AG | 211 | [23] |
VDR-BsmI | CAG TTC ACG CAA GAG CAG AG | ACC TGA AGG GAG ACG TAG CA | 236 | [24] |
VDR-Cdx2 G* VDR-Cdx2 A* | AGG ATA GAG AAAA TAA TAG AAA ACA TT TCC TGA GTA AAC TAG GTC ACA A | AAC CCA TAA TAA GAA ATA AGT TTT TAC ACG TTA AGT TCA GAA AGA TTA ATT C | 297 | [22] |
VDR-FokI | TGC AGC CTT CAC AGG TCA TA | GGC CTG CTT GCT GTT CTT AC | 157 | [25] |
VDR-NIaIII | TGC AGA GAA TGT CCC AAG GT | GTC CTG CCA GTC TGA TGG AT | 236 | [26] |
VDR-Tru91 | GCA GGG TAC AAA ACT TTG GAG | CCT CAT CAC CGA CAT CAT GTC | 177 | [19] |
Table 3Summary of the restriction enzyme digestion reactions and electrophoresis conditions for each VDR polymorphism
Gene variant | Restriction endonuclease | PCR product, µL | Digestion buffer | Other | Incubation length & temperature | Gel conditions - Agarose % | Fragment of gel, bp |
---|
VDR-A1012G | 20U EcoRV | 5 | 10x Buffer 4 (1 µL) | 3.8 µL H2O | 6 hr @ 37°C | 3 | AA: 150, 27 AG: 177, 150, 27 GG: 177 |
VDR-TaqI | 20U TaqI | 5 | 10x Buffer 4 (1 µL) | 1 µL BSA 2.8 µL H2O | 3 hr 20 min @ 65°C | 3 | TT: 211 Tt: 211, 172, 39 tt: 172, 39 |
VDR-ApaI | 50U ApaI | 5 | 10x Buffer 4 (1 µL) | 1 µL BSA 2.9 µL H2O | 3 hr @ 25°C | 3 | AA: 211 Aa: 211, 121, 90 aa: 121, 90 |
VDR-BsmI | 10U BsmI | 5 | 10x Buffer 4 (1 µL) | 3.5 µL H2O | 3 hr 20 min @ 65°C | 3 | BB: 236 Bb: 236, 197, 39 bb: 197, 39 |
VDR-Cdx2 G* VDR-Cdx2 A* | Not applicable | 3 | GG: 297, 110 AG: 297, 235, 110 AA: 297, 235 |
VDR-FokI | 4U FokI | 5 | 10x Buffer 4 (1 µL) | 3 µL H2O | 3.5 hr @ 37°C | 3 | FF: 157 Ff: 157, 121, 36 ff: 121, 36 |
VDR-NIaIII | 10U NIaIII | 5 | 10x Buffer 4 (1 µL) | 2.5 µL H2O | 6 hr @ 37°C | 3 | GG: 236 GC: 236, 197, 39 CC: 197, 39 |
VDR-Tru91 | 4U MseI | 5 | 10x Buffer 4 (1 µL) | 3 µL H2O | 3.5 hr @ 37°C | 3 | UU: 177 Uu: 177, 91, 86 uu: 91, 86 |
MMSE
The MMSE is a screening tool used to assess dementia, and focuses solely on the cognitive characteristics of mental functions, excluding questions involving mood, abnormal mental experiences and the form of thinking.27 The MMSE is comprised of 11 questions, covering: orientation to time; orientation to place; registration of three words; language; and visual construction. A score of more than 25 (out of 30) is classified as normal, whilst a score of 25 or less is indicative of some degree of cognitive decline.28
Food frequency questionnaire (FFQ)
Participants completed a self-administered FFQ, enabling an estimation of daily vitamin D intake. The FFQ was comprised of 38 questions relating to diet, covering 205 food items and all food groups. Participants also provided a full list of supplements they were taking, enabling an estimation of total dietary intake of vitamin D. Each FFQ was analysed in FoodWorks™ (version 6.0.2562) nutritional analysis software program (Xyris Software, Brisbane, QLD, Australia), providing a breakdown of vitamin D intake measured as an average per day. This software package is comprised of a number of different food databases, covering the majority of foods consumed by Australians. These include: Abbott products, Ausfoods (brand food) 2007, and Aus Nut (all foods) 2006.
Statistics
Statistical analysis was conducted using Microsoft Excel 2010 and JMP for Windows (version 11; SAS Institute Inc., Cary, NC, US). Age quartiles, sex and dietary vitamin D data distributions were examined, with mean, standard deviation (SD), median and interquartile range (IQR) reported as appropriate. Participants were stratified by sex and by cognitive decline based on the cut-off score of the MMSE (≤ 25 = cognitive decline; > 25 = no cognitive decline). Genotype prevalence (%), allele number (frequency) and carriage of polymorphic allele (%) were ascertained and tabulated according to cognitive decline. The degree and significance of an allele as a risk factor for a given biochemical/clinical phenotype was ascertained using an odds ratio (OR) and associated 95% confidence interval (CI).
The cognitive decline phenotype was defined as nominal data, and stepwise regression was used to create the best model, for subsequent nominal logistic regression analysis. Stepwise regression was performed in a mixed direction with significant probability [0.250] for a parameter to be considered as a forward step and entered into the model or considered as a backward step and removed from the model. Mallow’s Cp criterion was used for selecting the model where Cp first approaches p variables. R2 is reported and is the proportion of the variation in the response that can be attributed to terms in the model as opposed to random error. While an initial alpha level of 0.05 was set, Bonferroni corrections for multiple comparisons were also applied. Data is reported after adjusting for age and sex in analyses where stepwise regression modelling was used.
Results
Descriptive data for all subjects with and without cognitive decline is provided in Table 4, while the distribution of cognitive decline by age quartiles for each sex is given in Table 5. Seventy-three participants (11%) were found to exhibit some degree of cognitive decline based on their MMSE score. When examined by age quartiles, the proportion of participants with cognitive decline was highest in males in the 65–72 year-old group (15.2%) and the 73–80 year-old group (11.3%), and highest in females in the 81–88 year-old group (15.9%) and 89–95 year-old groups (28.6%) (Table 5). Total vitamin D intake (diet + supplements) was similar for participants with or without cognitive decline.
Table 4Descriptive data for all subjects and for those participants with and without cognitive decline, based on MMSE (≤25 = cognitive decline; >25 = no cognitive decline)
| All subjects | Cognitive decline | No cognitive decline |
---|
Number of participants | 650 | 73 (11%) | 575 (89%) |
Sex | | | |
Male | 287 | 33 (12%) | 253 (88%) |
Female | 363 | 40 (11%) | 322 (89%) |
Age, x ± SD; median (IQR) | 77. 8 ± 7.0; 78 (72–83); | 79.6 ± 7.6; 80 (74–86); | 77.5 ± 6.9; 78 (72–83); |
Total dietary vitamin D in µg/d, x ± SD; median (IQR) | 7.76 ± 11.54; 2.65 (1.77–7.93) | 8.41 ± 10.78; 2.87 (1.9–12.24) | 7.65 ± 11.61; 2.65 (1.75–7.41) |
Table 5Distribution of cognitive decline by age quartiles for each sex, based on MMSE (≤25 = cognitive decline; >25 = no cognitive decline) with percentage of participants with and without cognitive decline for each age quartile
| 65–72 yr | 73–80 yr | 81–88 yr | 89–95 yr |
---|
Males | Cognitive decline No cognitive decline | 12 (15%) 67 (85%) | 12 (11%) 94 (89%) | 8 (9%) 77 (91%) | 1 (6%) 15 (94%) |
Females | Cognitive decline No cognitive decline | 3 (3%) 85 (97%) | 12 (9%) 127 (91%) | 17 (16%) 90 (84%) | 8 (29%) 20 (71%) |
Table 6 presents the genetic distribution of each vitamin D-related polymorphism for the cognitive decline phenotype, and gives the genotype prevalence (%), allele number (frequency) and carriage of polymorphic allele (%). An OR and associated 95% CI were calculated to assess the degree of significance of risk for each of the vitamin D-related gene polymorphisms in relation to cognitive decline. Table 6 also shows that the VDR-BsmI and VDR-TaqI polymorphic alleles were both associated with an increased risk of cognitive decline (OR = 1.55, 95% CI: 1.08–2.22 and OR = 1.49, 95% CI: 1.04–2.14, respectively).
Table 6Occurrence of cognitive decline phenotype, based on MMSE (≤25 = cognitive decline; >25 = no cognitive decline), for genotype prevalence, allele number and carriage of polymorphic allele for vitamin D-related genetic polymorphisms
Polymorphism | Phenotype | Genotype prevalence (%)a
| Allele number (frequency)
| Carriage of polymorphic, allele % | Odds ratio | CI (Yates corrected p value) |
---|
Wildtype | Heterozygous | Recessive | Wildtype | Polymorphic |
---|
VDR-A1012G | Cognitive decline No cognitive decline | 22 (31) 185 (33) | 40 (56) 272 (48) | 10 (13) 108 (19) | 84 (0.58) 642 (0.57) | 60 (0.42) 488 (0.43) | 69 67 | | |
VDR-ApaI | Cognitive decline No cognitive decline | 14 (19) 120 (21) | 30 (41) 298 (53) | 29 (40) 148 (26) | 58 (0.40) 538 (0.48) | 88 (0.60) 594 (0.52) | 81 79 | | |
VDR-BsmI | Cognitive decline No cognitive decline | 22 (31) 207 (37) | 29 (40) 277 (49) | 21 (29) 79 (14) | 73 (0.51) 691 (0.61) | 71 (0.49) 435 (0.39) | 69 63 | 1.55 | 1.075–2.220 (0.0180) |
VDR-Cdx2 | Cognitive decline No cognitive decline | 12 (50) 87 (50) | 11 (46) 71 (41) | 1 (4) 15 (9) | 35 (0.73) 245 (0.71) | 13 (0.27) 101 (0.29) | 50 50 | | |
VDR-FokI | Cognitive decline No cognitive decline | 3 (12) 29 (17) | 10 (40) 85 (49) | 12 (48) 61 (34) | 16 (0.32) 143 (0.41) | 34 (0.68) 207 (0.59) | 88 83 | | |
VDR-NlaIII | Cognitive decline No cognitive decline | 10 (40) 56 (32) | 13 (52) 87 (50) | 2 (8) 32 (18) | 33 (0.66) 199 (0.57) | 17 (0.34) 151 (0.43) | 60 68 | | |
VDR-TaqI | Cognitive decline No cognitive decline | 25 (34) 203 (37) | 27 (37) 280 (51) | 21 (29) 66 (12) | 77 (0.53) 686 (0.62) | 69 (0.47) 412 (0.38) | 66 63 | 1.49 | 1.039–2.142 (0.0290) |
VDR-Tru91 | Cognitive decline No cognitive decline | 59 (81) 414 (73) | 13 (18) 138 (24) | 1 (1) 16 (3) | 131 (0.90) 966 (0.85) | 15 (0.10) 170 (0.15) | 19 27 | | |
Multivariate analyses of all vitamin D-related genetic polymorphisms using stepwise regression showed a significant relationship between VDR-TaqI and MMSE (p = 0.0014; R2 = 0.0292). When adjusted for age and sex, the relationship between VDR-TaqI and MMSE remained significant (p = 0.0004; R2 = 0.0473). Both results upheld their significance following a Bonferroni correction. To further examine the significant relationship between VDR-TaqI and MMSE, the percentage of participants with cognitive decline for each genotype was calculated. Figure 3 shows that the highest percentage of participants with some degree of cognitive decline was amongst those with the homozygous recessive tt genotype (24%).
Nominal logistic regression analysis was used to examine the relationships between other variables and MMSE score, independent of genetic influence. Results showed a significant inverse association between age and MMSE score (p = 0.0145; R2 = 0.0131; slope estimate = −0.0180), and when examined by sex, a significant relationship was shown between age and MMSE for females (p ≤ 0.0001; R2 = 0.0865; slope estimate = −0.1160) but not males.
Discussion
The present study examined the relationship between VDR polymorphisms and cognition in 650 elderly participants using the MMSE to assess their degree of cognitive decline. An OR analysis showed that both the VDR-BsmI and VDR-TaqI polymorphic alleles increased the risk of cognitive decline and that the VDR-TaqI genetic polymorphism was also significantly associated with MMSE score. The percentage of participants with some degree of cognitive decline was highest amongst those with the VDR-TaqI homozygous recessive tt genotype (24%).
Vitamin D is important for brain and other physiological functions, and plays an important role in the biosynthesis of neurotransmitters,4 neuroprotection,5 immunomodulation and detoxification.4 Consequently, some of these biological effects suggest that vitamin D may influence cognitive function and mood disorders. Evidence surrounding vitamin D and the human brain have revealed individuals are increasingly vulnerable to mood disorders during the winter months,29,30 and a vitamin D deficiency may contribute to seasonal affective disorder. Additionally, evidence has shown a link between low vitamin D status and mood disorders, accompanied with poor cognitive function.31 Balion et al.32 conducted a systematic review and meta-analysis to examine the association between vitamin D, cognitive function and MMSE score; overall, it was found that lower vitamin D concentrations were associated with poorer cognitive scores and higher AD risk. In the present study, no associations were found between dietary vitamin D intake and MMSE score.
Research surrounding VDR polymorphisms and cognition have mostly focused on AD,33,34 and to a lesser extent cognitive decline.35 In one study, a meta-analysis found associations between VDR polymorphisms and AD and Parkinson’s disease (PD) susceptibility.36 Other findings include a significant association between the VDR-TaqI “T” allele and AD susceptibility (OR = 0.735, 95% CI: 0.596–0.907),36 while in a further study the VDR-ApaI A allele and AA genotype increased the risk of mild cognitive impairment (MCI) (OR = 1.62, 95%CI: 1.13–2.31 and OR = 3.49, 95% CI: 1.570–7.740, respectively).24 The results also showed that the variant B allele of VDR-BsmI increased the risk of MCI (OR = 1.94, 95% CI: 1.240–3.050).37
Najmi Varzaneh et al.38 found the VDR-FokI was significantly associated with cognitive function following assessment using the MMSE. Examination of cognitive function amongst FokI genotypes showed “FF” participants had a higher cognitive score compared with “ff” participants.38 Similar findings were shown for FokI in a recent longitudinal study by Gatto et al.39 This study examined VDR polymorphisms with PD using the MMSE, and found that for each additional copy of the FokI-A allele (also referred to as the “f” allele) an associated decrease in the total MMSE score occurred. Furthermore, their results indicated that participants with the AA genotype (also referred to as “ff” genotype) had a faster decline in cognitive function than participants with other VDR-FokI genotypes. No significant association was found between any other VDR polymorphism and PD in this study based on a level of significance of p < 0.05.39
Another study involving elderly subjects found significant associations between VDR-BsmI, VDR-TaqI and a low composite cognitive score (calculated by averaging the scores of other cognitive function tests) but not with a low MMSE score.40 Additionally, a significant association was observed between VDR-ApaI and less depressive symptoms based on the Geriatric Depression Scale.40
Since vitamin D was the nutrient of particular interest, blood 25(OH)D3 measurements would have provided further details surrounding the vitamin D status of participants. This is therefore a limitation in the present study.
Future research directions
Further research is necessary to either confirm or refute the presently observed associations of VDR gene variants with cognitive decline as measured using the MMSE scale. By obtaining a more thorough understanding of VDR variants and their influence on risk of cognitive decline, new insights into the underlying pathophysiology of cognitive decline and development of possible intervention and treatment strategies will emerge. These may include the screening of particular VDR polymorphisms as part of a routine health check and the use of supplemental vitamin D at a younger age. Based on the preliminary results of this study, we hypothesize that the use of vitamin D as a potential preventative agent in cognitive decline will reduce the impact this degenerative disorder currently has on our health system.
Conclusions
Our results show that the VDR-BsmI and VDR-TaqI polymorphisms are associated with cognitive decline in an elderly population. Since the elderly are particularly at risk for a number of degenerative disorders related to low serum 25(OH)D3 levels, including cognitive decline, further exploration of the influence of VDR gene variants is necessary to reveal the full extent of potential interactions.
Abbreviations
- AD:
Alzheimer’s disease
- CI:
confidence interval
- FFQ:
food frequency questionnaire
- MCI:
mild cognitive impairment
- MMSE:
mini mental state examination
- OR:
odds ratio
- PD:
Parkinson’s disease
- PCR:
polymerase chain reaction
- RFLP:
restriction fragment length polymorphism
- RHLS:
Retirement Health and Lifestyle Study
- SNP:
single nucleotide polymorphism
- UVR:
ultraviolet radiation
- VDR:
vitamin D receptor
Declarations
Acknowledgement
Part of the research on which this paper is based was conducted as part of the Retirement Health and Lifestyle Study, The University of Newcastle. We are grateful to the Australian Research Council, Central Coast Local Health District Public Health Unit, UnitingCare Ageing NSW/ACT, Urbis Pty Ltd, Valhalla Village Pty Ltd, and Hunter Valley Research Foundation for funding the initial study and to the men and women of the Central Coast region who provided the information recorded. The authors would also like to thank the researchers and RHLS clinic staff based at Gosford Teaching Unit, including Jenny Marriott, Marie Mazaroli, Elizabeth Death, Jodi Humphreys, and Louise Lambeth. This research was supported by an Australian Research Council linkage grant (G0188386) awarded to Martin Veysey (lead CI).
Conflict of interest
The authors have no conflict of interests related to this publication.
Authors’ contributions
Study design (CM, ML), performance of experiments (CM), analysis and interpretation of data (CM, ML), manuscript writing (CM, ZY, MV), critical revision of the manuscript (CM, ZY, KK, SN, ML), statistical analysis (CM), providing critical funding (MV).